Cartesian Therapeutics Statistics
Share Statistics
Cartesian Therapeutics has 25.73M shares outstanding. The number of shares has increased by -84.12% in one year.
| Shares Outstanding | 25.73M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 20.28% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 8.47M |
| Failed to Deliver (FTD) Shares | 2.08K |
| FTD / Avg. Volume | 1.7% |
Short Selling Information
The latest short interest is 1.80M, so 6.98% of the outstanding shares have been sold short.
| Short Interest | 1.80M |
| Short % of Shares Out | 6.98% |
| Short % of Float | 16.79% |
| Short Ratio (days to cover) | 12.54 |
Valuation Ratios
The PE ratio is -0.46 and the forward PE ratio is -4.87.
| PE Ratio | -0.46 |
| Forward PE | -4.87 |
| PS Ratio | 3.91 |
| Forward PS | 52.6 |
| PB Ratio | -0.23 |
| P/FCF Ratio | -1.98 |
| PEG Ratio | n/a |
Enterprise Valuation
Cartesian Therapeutics Inc. has an Enterprise Value (EV) of 35.49M.
| EV / Earnings | -0.16 |
| EV / Sales | 1.36 |
| EV / EBITDA | -0.15 |
| EV / EBIT | -0.41 |
| EV / FCF | -0.69 |
Financial Position
The company has a current ratio of 1.33, with a Debt / Equity ratio of -0.02.
| Current Ratio | 1.33 |
| Quick Ratio | 1.33 |
| Debt / Equity | -0.02 |
| Total Debt / Capitalization | -2.55 |
| Cash Flow / Debt | -4.67 |
| Interest Coverage | -30.5 |
Financial Efficiency
Return on equity (ROE) is 0.5% and return on capital (ROIC) is 18.53%.
| Return on Equity (ROE) | 0.5% |
| Return on Assets (ROA) | -0.72% |
| Return on Capital (ROIC) | 18.53% |
| Revenue Per Employee | 702.81K |
| Profits Per Employee | -5.94M |
| Employee Count | 37 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -19.00M |
| Effective Tax Rate | 0.08 |
Stock Price Statistics
The stock price has increased by -38.78% in the last 52 weeks. The beta is 0, so Cartesian Therapeutics 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -38.78% |
| 50-Day Moving Average | 19.11 |
| 200-Day Moving Average | 19.79 |
| Relative Strength Index (RSI) | 47.35 |
| Average Volume (20 Days) | 122.37K |
Income Statement
In the last 12 months, Cartesian Therapeutics had revenue of 26.00M and earned -219.71M in profits. Earnings per share was -42.49.
| Revenue | 26.00M |
| Gross Profit | 24.45M |
| Operating Income | -86.42M |
| Net Income | -219.71M |
| EBITDA | -235.06M |
| EBIT | -86.42M |
| Earnings Per Share (EPS) | -42.49 |
Balance Sheet
The company has 76.91M in cash and 10.96M in debt, giving a net cash position of 65.96M.
| Cash & Cash Equivalents | 76.91M |
| Total Debt | 10.96M |
| Net Cash | 65.96M |
| Retained Earnings | -614.65M |
| Total Assets | 455.32M |
| Working Capital | 207.73M |
Cash Flow
In the last 12 months, operating cash flow was -51.16M and capital expenditures -206.00K, giving a free cash flow of -51.37M.
| Operating Cash Flow | -51.16M |
| Capital Expenditures | -206.00K |
| Free Cash Flow | -51.37M |
| FCF Per Share | -9.93 |
Margins
Gross margin is 94.03%, with operating and profit margins of -332.32% and -844.91%.
| Gross Margin | 94.03% |
| Operating Margin | -332.32% |
| Pretax Margin | -917.97% |
| Profit Margin | -844.91% |
| EBITDA Margin | -903.95% |
| EBIT Margin | -332.32% |
| FCF Margin | -197.53% |
Dividends & Yields
RNAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -236.06% |
| FCF Yield | -11.09% |
Analyst Forecast
The average price target for RNAC is $41.5, which is 130.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $41.5 |
| Price Target Difference | 130.6% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Apr 5, 2024. It was a backward split with a ratio of 1:30.
| Last Split Date | Apr 5, 2024 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -2.78 |
| Piotroski F-Score | 3 |